Achim Rittmeyer
Overview
Explore the profile of Achim Rittmeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
6170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
2.
Hochmair M, Schenker M, Cobo Dols M, Kim T, Ozyilkan O, Smagina M, et al.
J Thorac Oncol
. 2024 Oct;
20(2):203-218.
PMID: 39477187
Introduction: Poly (adenosine diphosphate-ribose) polymerase inhibitors can up-regulate programmed cell death-ligand 1 expression and promote immune-mediated responses and may improve efficacy of first-line anti‒programmed cell death protein 1‒based therapies in...
3.
Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, et al.
Clin Lung Cancer
. 2024 Aug;
25(8):672-682.e5.
PMID: 39153867
Purpose: MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi)....
4.
Ziegler D, Cleve C, Ziegler S, Schirmer M, Fischer L, Bohnenberger H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893074
In this study, we investigated the outcomes and factors influencing treatment efficacy in 93 patients with limited disease small cell lung cancer (LD-SCLC), with a median age of 64 years....
5.
Stratmann J, Althoff F, Doebel P, Rauh J, Trummer A, Hunerliturkoglu A, et al.
Eur J Cancer
. 2024 Feb;
201:113911.
PMID: 38377774
Background: Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the...
6.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Luders H, et al.
J Thorac Oncol
. 2023 Dec;
19(5):803-817.
PMID: 38096950
Introduction: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing...
7.
Rudin C, Liu S, Soo R, Lu S, Hong M, Lee J, et al.
J Clin Oncol
. 2023 Nov;
42(3):324-335.
PMID: 37976444
Purpose: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung...
8.
Mhatre S, Machado R, Ton T, Trinh H, Mazieres J, Rittmeyer A, et al.
Clin Pharmacol Ther
. 2023 Sep;
114(6):1313-1322.
PMID: 37696652
Evaluating cancer treatments in real-world data (RWD) requires informative endpoints. This study replicated the atezolizumab and docetaxel arms of the OAK trial using RWD and compared progression-free survival (PFS) outcomes...
9.
Lee S, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, et al.
Lancet
. 2023 Jul;
402(10400):451-463.
PMID: 37423228
Background: Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG...
10.
Overbeck T, Reiffert A, Schmitz K, Rittmeyer A, Korber W, Hugo S, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296928
(1) Background: The main objectives of our study are (i) to determine the prevalence of () fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii)...